The stock of Taysha Gene Therapies Inc (TSHA) has gone down by -9.09% for the week, with a -30.64% drop in the past month and a -36.17% drop in the past quarter. The volatility ratio for the week is 12.59%, and the volatility levels for the past 30 days are 11.24% for TSHA. The simple moving average for the last 20 days is -23.09% for TSHA stock, with a simple moving average of -39.05% for the last 200 days.
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
Company’s 36-month beta value is 1.03.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 165.01M, and currently, short sellers hold a 15.30% ratio of that floaft. The average trading volume of TSHA on April 10, 2025 was 2.17M shares.
TSHA) stock’s latest price update
Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has plunge by 6.19relation to previous closing price of 1.13. Nevertheless, the company has seen a -9.09% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-04 that DALLAS, April 04, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted five new employees, in the aggregate, options to purchase 822,000 shares of the Company’s common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at -25.41% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.22% of loss for the given period.
Volatility was left at 11.24%, however, over the last 30 days, the volatility rate increased by 12.59%, as shares sank -31.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.00% lower at present.
During the last 5 trading sessions, TSHA fell by -9.09%, which changed the moving average for the period of 200-days by -59.46% in comparison to the 20-day moving average, which settled at $1.5603. In addition, Taysha Gene Therapies Inc saw -30.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 1,333,333 shares at the price of $2.25 back on Jun 27 ’24. After this action, Manning Paul B now owns 1,333,333 shares of Taysha Gene Therapies Inc, valued at $2,999,999 using the latest closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -10.98 for the present operating margin
- 1.0 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -10.72. The total capital return value is set at -0.68. Equity return is now at value -121.94, with -32.87 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -1.29. The debt to equity ratio resting at 0.88. The interest coverage ratio of the stock is -896.66.
Currently, EBITDA for the company is -87.95 million with net debt to EBITDA at 0.86. When we switch over and look at the enterprise to sales, we see a ratio of 20.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
In a nutshell, Taysha Gene Therapies Inc (TSHA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
